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Six intraoperative blood samples were obtained at 
intervals from each of 100 individuals undergoing their 
first liver transplants. The patients fell into the follow-
ing diagnostic categories: post necrotic cirrhosis 28, pri-
mary biliary cirrhosis 20, sclerosing cholangitis 19, 
miscellaneous diseases 14, carcinoma/neoplasia 12 and 
fulminant hepatitis 7. Coagulation factor values in the 
initial (baseline) blood samples varied by patient diag-
nosis. In general, all factor levels were reduced except 
factor VIII:C, which was increased to almost twice nor-
mal. The slight intraoperative changes in factors II, VII, 
IX, X, XI and XII suggested that a steady-state relation-
ship existed between depletion (consumption/bleeding) 
and repletion (transfusion, transit from extra- to intra-
vascular space), even in the anhepatic state. In contrast, 
there were rapid and very significant falls in factor VIII 
and fibrinogen and a less pronounced decrease in factor 
V, all reaching their nadirs in early to mid-Stage III. 
The cause of these coagulation changes appears to be 
activation of the fibrinolytic system. 
Liver transplantation has been used to treat end-stage 
liver disease caused by a wide variety of congenital or 
acquired disorders. Improved methods for procurement 
and preservation of the donor livers, innovative surgical 
techniques and improved immunosuppressive agents 
have made liver transplantation feasible for many pa-
tients with severely damaged liver parenchyma, vascu-
lature or bile ducts. However, one ofthe major difficulties 
has been the need for multiple blood transfusions, which 
reflects the large loss of blood during the operation. This 
study deals with intraoperative changes in coagulation 
parameters and the quantities of red blood cells (RBC) 
transfused. 
MATERIALS AND METHODS 
Patients. During an approximate 2-year period, intra-
operative coagulation studies were carried out on 100 adult 
individuals undergoing their first liver transplants. All of these 
transplants were done with an axillofemoral venous bypass 
using tubing with a heparinized surface (ARGYLE'" tubing) 
which shunted the major blood flow away from the operative 
area. No patient received systemic heparin. All patients were 
transfused with a premixed "cocktail" of equal volumes (250 
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ml) of RBC, fresh-frozen plasma and Plasmalyte At>, which 
contained 526 mg per 100 ml sodium chloride, 502 mg per 100 
ml sodium gluconate, 368 mg per 100 ml sodium acetate trihy-
drate, 37 mg per 100 ml potassium chloride, 30 mg per 100 ml 
magnesium chloride adjusted with sodium hydroxide to pH 
range 6.5 to 8.0. Previous testing of this mixture had shown the 
following mean values: hematocrit 27%, factor I (fibrinogen) 
0.37 unit per ml, factor II (prothrombin) 0.59 unit per ml, factor 
V 0.21 unit per ml, factor VII 0.58 unit per ml and factor VIII 
0.57 unit per ml (1). Transfusions of platelets and cryoprecip-
itate were usually started in Stage III. Intraoperative coagula-
tion studies were performed at the request of the anesthesiol-
ogist or surgeon who had informed the patient that these would 
be necessary for regulation of therapy (plasma, RBCs, platelets, 
etc.). 
The patients were categorized by pathological diagnosis as 
previously described (2). An additional diagnostic group, ful-
minant hepatitis, was included. The 100 patients fell into the 
six diagnostic groups shown in Table 1. The largest group 
comprised 28 patients with postnecrotic cirrhosis (PNC) and 
included patients with chronic active hepatitis, lupoid hepatitis 
or cryptogenic cirrhosis. The second largest group contained 20 
female patients with primary biliary cirrhosis (PBC). An ad-
ditional19 patients had primary sclerosing cholangitis (SC). In 
the carcinoma/neoplasia (CA) group, eight patients had hepa-
tomas, one of whom had preexisting cirrhosis secondary to 
congenital tyrosinemia. Three patients had angiosarcoma, and 
one patient, with a metastatic tumor of unknown primary site, 
was thought to have a vascular hepatic tumor preoperatively. 
In the smallest group, containing seven patients with fulmi-
nant hepatitis (FUL), three were presumed to be infected with 
non-A, non-B hepatitis, one was infected with hepatitis B, two 
were secondary to hepatotoxins (gold and 2-nitropropane) and 
one was of unknown etiology. 
A final miscellaneous (MIS) group included 14 patients with 
various diagnoses. Three patients had Wilson's disease, and 
there was one patient with each of the following diagnoses: 0',-
antitrypsin deficiency, hemachromatosis, Budd-Chiari syn-
drome, cirrhosis secondary to cystic fibrosis, polycystic disease 
of the liver, secondary biliary cirrhosis, congenital hepatic 
fibrosis, variant Caroli's disease (secondary biliary cholangiec-
tasis), acquired hepatocerebral degeneration and cryptococcal 
cholangitis; a final patient had bile duct obstruction and cho-
langitis secondary to hepatic trauma. 
Coagulation Tests. The tests performed employed pre-
viously published methods (3-5) and included prothrombin 
time (PT), activated partial thromboplastin time (APTT), eu-
globulin lysis time (EL T) and assays of coagulation factors I, 
II, V, VII, VIII, IX, X, XI and XII. Fibrinogen was expressed 
as units per ml by dividing the mg per dl by 300 mg per dI (the 
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normal value for this laboratory). Commercially obtained 
standards (lyophilized) and locally produced frozen pooled 
plasma were tested with each group of assays (approximately 
every 2 hr). All blood samples for these tests were chilled 
immediately, centrifuged in the cold and assayed as rapidly as 
possible. The euglobulin lysis time is a crude but rapid screening 
test for the presence of fibrinolytic activity. The euglobulin 
fraction used in the test contains most of the activator, plas-
minogen and fibrinogen in the original plasma. The actual lysis 
time is dependent upon the concentrations of these factors and 
any traces of inhibitors which might be coprecipitated. 
For various reasons, not all coagulation tests were done on 
all samples (see sample numbers in parentheses, Table 2). The 
PT and APTT were done on all six samples from 55 patients; 
the ELT, fibrinogen and factor X were performed on six sam-
ples from 99 patients. Other factors were assayed on the six 
samples from the 100 patients. 
Blood Sample Timing. Because the coagulation tests 
were performed as part of patient care and not as a research 
project, the timing varied somewhat from patient to patient. 
Each operation took from 6 to 12 hr or more. Stage I was the 
operative stage in which the diseased liver was dissected and 
removed and the site for the new liver was prepared; it lasted 
for 2 to 5 hr. Stage II was the time during which the liver was 
separated from the circulation and removed from the body-
the anhepatic period; it usually lasted about 2 hr. Stage III was 
TABLE 1. Diagnostic categories of 100 patients undergoing 
first liver transplants 
No. Female Male Age range (years) 
PNC 28 14 14 16-52 
PBC 20 20 0 27-54 
SC 19 7 12 23-54 
MIS 14 6 8 16-47 
CA 12 8 4 21-54 
FUL 7 0 7 27-57 
Total 100 55 45 16-57 
the period during which the new liver was inserted into the 
prepared bed, the circulation was established and bile ducts 
were revised. This took from 4 to 6 hr. 
Multiple serial samples were taken during each operation at 
times when the anesthesiologist or surgeon anticipated prob-
lems. Only the six which fitted into the pattern shown in Table 
3 were used in this study. If two or more samples fell within 
the same time period, the test results were averaged. 
Blood Use. The number of units of RBCs used are the 
figures compiled by Central Blood Bank (number of units 
released to patient minus number returned) and may differ 
slightly from the records of the anesthesiologists. 
Plot Patterns. The data for each liver transplant were 
fitted into the blood sample timing pattern (Figs. 1 to 4). The 
stage of the operation is indicated on the abscissa. The mean 
duration of the 100 transplants was 10 hr. Each tick on the 
abscissa indicates 1 hr. The ordinate for Figure 1 gives the PT 
and APTT in sec and the EL T in min. The ordinates in Figures 
2 to 4 are in units per m!. 
Statistical Analysis. Analysis of variance was calculated 
on intraoperative data using the Statistical Analysis System's 
general linear model [po 434 of Ref. (6)], in which t tests were 
performed on intraoperative means to calculate least significant 
differences. Only confidence levels of 0.01 or less were consid-
TABLE 3. Blood sample timing patterns 
Stage Sample Average time (hr) Period 
no. from skin incision 
1 0 Initial or baseline 
2 3.5 Late in Stage I (following 
dissection of diseased 
liver) 
II 3 5.5 Mid- to late Stage II (an-
hepatic period) 
III 4 6.4 Early in Stage III (resto-
ration of circulation to 
the new graft liver) 
5 8 Mid-Stage III 
6 10 End of operation 
TABLE 2. Statistical analysis of data shown in Figures 1 to 4a 
Test (no. of specimens) 
Sample Figure 1 Figure 2 Figure 3 Figure 4 
comparisons 
PT APTT ELT II V VII X I IX XI XII VIII 
(330) (330) (594) (600) (600) (600) (594) (594) (600) (600) (600) (600) 
1-2 NS b NS 0.00001 NS 0.Q1 NS NS 0.01 NS NS NS NS 
1-3 NS NS 0.00001 NS 0.00001 NS 0.Q1 0.00001 NS NS NS 0.00001 
1-4 0.01 0.00001 0.00001 0.00001 0.00001 0.0001 0.00001 0.00001 0.00001 NS 0.001 0.00001 
1-5 NS 0.01 NS 0.00001 0.00001 0.Q1 0.00001 0.00001 0.00001 NS 0.001 0.00001 
1-6 NS NS NS 0.01 0.00001 NS 0.00001 0.00001 NS NS NS 0.00001 
2-3 NS NS NS NS NS NS NS NS NS NS NS 0.00001 
2-4 0.001 0.00001 NS 0.0001 0.00001 0.Q1 0.00001 0.0001 0.00001 NS 0.Q1 0.00001 
2-5 0.Q1 0.001 0.01 0.0001 0.00001 NS 0.00001 0.0001 0.0001 NS 0.01 0.00001 
2-6 NS NS 0.00001 NS 0.00001 NS 0.00001 0.01 NS NS NS 0.00001 
3--4 0.001 0.00001 NS 0.001 0.00001 NS 0.00001 NS 0.0001 NS NS 0.00001 
3-5 0.01 0.001 0.00001 0.01 0.00001 NS 0.00001 NS NS NS NS 0.00001 
3-6 NS NS 0.00001 NS 0.00001 NS NS NS NS 0.01 NS 0.00001 
4-5 NS 0.Q1 0.00001 NS NS NS NS NS NS NS NS NS 
4-6 NS 0.00001 0.00001 0.Q1 NS NS NS NS 0.00001 0.001 NS NS 
5-6 NS 0.001 0.Q1 0.01 NS NS 0.01 NS 0.01 NS NS NS 
a Alpha or p value for the significance of differences among the means of coagulation tests at different stages in liver transplantation. The 
outer column of sample numbers indicates the sample value which is being compared to that in the second list. 
b NS = not significant. 
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FIG. 1. Prothrombin time (PT) (sec), activated partial thromboplas-
tin time (APTT) (sec) and euglobulin lysis time (ELT) (min). 
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FIG. 3. Factors I (fibrinogen), IX, XI and XII. 
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FIG. 4. Factor VIn (note scale change). 
ered significant. Relationships between EL T, blood use and 
factor levels used ANOVA [po 609 of Ref. (6)), a standard 
analysis of variance in addition to the nonparametric perform-
ance of ranks. 
RESULTS 
Figures 1 to 4 present means of the coagulation tests 
and factors, and Table 2 shows the alpha or p values for 
the significance of the difference for each mean from the 
others. In Table 2, the numbers in parentheses after the 
name of the test indicate the number of values used in 
the calculation. For example, for PT only 330 points 
were used. This means that only 55 patients had PT 
values for each timed sample, whereas factor II calcula-
tions used 600 points, indicating that all 100 patients 
had the six needed results. 
Prothrombin Time and Activated Partial 
Thromplastin Time. PT and APTT are plotted on 
the seconds time scale of Figure 1. Both are abnormal in 
Sample 1. The PT curve is nearly flat and only Point 4 
is significantly different from the others. The APTT 
curve shows a sharp, highly significant rise at Points 4 
and 5, returning to normal at the end of the operation. 
Eugloblin Lysis Time. The ELTon the initial 
sample (Fig. 1) was within the normal range (>120 min) 
in 78% of the 99 patients tested. Mildly activated initial 
lysis times were found in 14/28 (50%) of the PNC group, 
6/14 (43%) of the MIS group, 1/12 (8%) of the CA group 
and 1/7 (14%) of the FUL group. None of the baseline 
studies on PBC or SC patients showed activated EL T 
times. Figure 1 shows that the EL T times decreased 
rapidly and were very significantly different from base-
line on Samples 2, 3 and 4. By the middle of Stage III 
and end of operation, the EL Ts had returned to normal. 
Factors II, V, VII and X. Inspection of Figure 2 
shows that the time curve for all four factors followed 
very similar patterns. The major decline in activity 
started late in the anhepatic stage and reached its nadir 
at Sample 4. Samples 5 and 6 showed minor recoveries 
in factors II, VII and X but essentially no recovery in 
factor V. All of the intraoperative factor V assays were 
below the baseline value and there was little or no 
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recovery. Factor X's baseline assay was higher than that 
of the other factors, making the fall at Sample 4 appear 
more precipitous. 
Factors I, IX, XI and XII. Fibrinogen and factor 
IX (Fig. 3) started to fall with the second sample and 
showed a poor recovery by the end of the operation. The 
curve for factor XI was almost flat. For factor XII there 
was a moderately significant decline from Sample 1 to 
Sample 4 with recovery in Samples 5 and 6. 
Factor VIII. Factor VIII levels were plotted on a 
separate chart (Fig. 4) to allow inclusion of the initial 
very high level and the steep decline during the anhepatic 
stage and early Stage III. There was no significant recov-
ery at the end of the procedure. 
Blood Use. The mean RBC use during these 100 
operations was 26.3 units, and the range was from 4 to 
157 units. 
Relationships between Coagulation Factor 
Rank, ELT and RBC Use. In order to determine 
whether or not the coagulation factor levels were de-
pendent on the presence or absence of active fibrinolysis 
or were a determinant in the amount of blood used, the 
lowest levels of each were ranked. The lowest level was 
determined by picking (by computer) the least value of 
the factor on Samples 3, 4 or 5. These values were then 
ranked from 1 to 99 or 100. The first and second ELT 
columns of Table 4 show the mean EL T values for the 
lowest 20 and highest 79 patients ranked for fibrinogen. 
These are obviously different in comparison to the next 
line, factor II, which are almost the same for the low 20 
and high 79. Factors VIII, XII, V and XI are dependent 
to a significant extent on the ELT. The last section of 
Table 4 shows the mean numbers of RBC units used in 
the low-rank 20 patients and the high-rank 80. This 
indicates that low levels of factor VIII, in particular, 
correlate with high use of RBCs. Fibrinogen, factor IX, 
factor XII and EL T to a lesser extent correlate with 
blood use. 
DISCUSSION 
Several points may be made by the analysis of the 
coagulation tests and factor levels during liver transplan-
tation. The PT and APTT lengthen significantly during 
TABLE 4. Relationship between coagulation factor rank (low 
20 and high 79 or 80), ELT score and RBC use a 
ELT score RBC units 
Factor Low High Low High 
20 79 p 20 80 P 
FIBb 1.8 2.59 0.007 43 22 0.0033 
II 2.4 2.44 NS 32 25 NS 
V 1.95 2.56 0.04 29 26 NS 
VII 2.05 2.53 NS 21 28 NS 
VIII 1.70 2.62 0.0016 60 18 0.0001 
IX 2.10 2.52 NS 40 23 0.02 
X 2.35 2.46 NS 23 27 NS 
XI 1.95 2.56 0.04 35 24 NS 
XII 1.90 2.57 0.02 39 23 0.02 
ELT 1.0 2.78 0.0001 38 23 0.04 
a EL T score = 1 for 15 min, 2 for 30 min, 3 for 45 min, and 4 for 60 
min or more. 
b FIB = fibrinogen (factor I). 
liver transplantation. The PT and APTT lengthen sig-
nificantlyat Sample 4 (early Stage III) and return toward 
normal by the end of the operation. The coagulation 
factor assays follow the same pattern. Factors II, VII, X, 
IX and XII fall during the anhepatic period, reaching 
their nadirs early in Stage III, and return to or toward 
the baseline value by the end of the operation. Factors I, 
V and VIII start to fall somewhat earlier and have made 
lesser recoveries by the end of the surgery. If the factor 
starts at below-normal levels, which is often the case 
when the liver parenchymal cells are damaged, a correc-
tion may be seen in the first hours, undoubtedly due to 
the infusion of fluids containing factors at higher levels 
than those circulating in the recipient. During the an-
hepatic phase, when there is little or no synthesis of 
most coagulation factors, highly significant declines, ex-
cept in factor XI, are observed. For factor XI, we must 
presume that inflow from infusion and extravascular 
areas and, possibly, a slower ratio of metabolic break-
down due to long (24 to 48 hr) half-life, almost balance 
the outflow due to blood loss and lack of synthesis. 
The activation of fibrinolysis and its effects on coag-
ulation factor levels were studied by ranking the intra-
operative levels of each factor into two groups: the lowest 
20 and the highest 79 (Table 4). The mean ELT number, 
indicating extent of activation of EL Ts in each group, 
was determined. The relationships between activation of 
fibrinolysis and decreases in factors VIII and I are highly 
significant and in factors V, XI and XII are slightly 
significant. Thus, the sequence of events appears to be 
activation of fibrinolysis in late Stage II followed by 
destruction of factors I and VIII with concomitant ele-
vation ofthe APTT early in Stage III. Factors V, XI and 
XII also seem susceptible to fibrinolytic destruction. 
Fibrinolysis may be activated by release of tissue plas-
minogen activator from vascular endothelium or possibly 
by inhibition of tissue plasminogen activator inhibitor 
by activated Protein C. It is theorized that in either case 
active plasmin is formed in quantities sufficient to de-
stroy the susceptible coagulation factors (VIII, V and I). 
Previous investigations of coagulation during canine 
and/or human liver transplantation and in human liver 
disease have been alternatively interpreted to show 
strong evidence for activation of fibrinolysis (7, 8), for 
disseminated intravascular coagulation (DIe) (9-12) or 
for both (13). 
DIC (14) causes consumption of multiple coagulation 
factors, antithrombin III and platelets and the appear-
ance of high levels of fibrin monomers, fibrin split prod-
ucts and microthrombi (7). In an early study of human 
and canine graft livers, the presence of microthrombi 
could not be demonstrated (10). This, however, does not 
rule out DIe since microthrombi could be lysed in situ. 
In addition, the limited falls in the coagulation factors 
and the lack of high levels of fibrin split products (15) 
indicate that DIC is mild or absent. Recently presented 
but unpublished data from our own laboratory show no 
significant change in antithrombin III during liver trans-
plantation. These findings do not support the contention 
that DIe is the major cause of the changes observed 
during liver transplantation. A fibrinolytic process is 
more consistent with the findings. 
------------------------
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The clinical importance of rapid and abrupt decline in 
factor VIII values is emphasized by the highly significant 
relationship between blood use and rank by lowest factor 
VIII value. Operations in which factor VIII fell into the 
lowest 20% used three times as much blood as did the 
80% with higher factor VIII levels. 
Recent thromboelastographic evidence (15), as well as 
these observations, support fibrinolysis as the predomi-
nant mechanism involved. Therapeutic intervention to 
counteract fibrinolysis (AmicarC!\l and Cyklokapron®) may 
help to clarify its role and lead to prevention of life-
threatening hemorrhage. Cryoprecipitate and/or heat-
treated or virus-free factor VIII concentrates are avail-
able for treatment of the factor VIII deficiency. 
Our results indicate that the most informative tests 
are PT, APTT, ELT and factor VIII level performed six 
to eight times (at 2- to 3-hr intervals) during the surgery. 
Platelet counts are also recommended to guide platelet 
replacement therapy. 
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